SAILIFE1,591.50

Sai Life Sciences Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSYNGENEDIVISLABPPLPHARMANHNEULANDLABNATCOPHARMLALPATHLABCOHANCEMcap ₹33,705 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,694.62,192.52,250.4
Other Income36.849.142.8
Total Income1,731.32,241.62,293.1
Expenses
+ Cost of Materials Consumed460.8578.1654.8
+ Changes in Inventories5.0-7.2-80.1
+ Employee Benefit Expense549.1683.1702.3
+ Finance Costs76.239.234.5
+ Depreciation & Amortisation138.6166.9175.1
+ Other Expenses274.0307.4315.1
Total Expenses1,503.61,767.41,801.7
EBITDA405.7631.2658.2
EBIT267.1464.3483.2
Profit
PBT before Exceptional Items227.7474.2491.4
+ Exceptional Items0.0-8.0-8.0
Pretax Income227.7466.2483.4
+ Current Tax33.888.494.0
+ Deferred Tax23.728.927.6
Tax Expense57.6117.3121.7
Net Income170.1348.9361.7
+ Net Income — Continuing Ops170.1348.9361.7
+ Other Comprehensive Income1.2-20.8-2.7
Total Comprehensive Income171.3328.1359.0
Per Share
Basic EPS8.8316.6317.17
Diluted EPS8.6116.4316.93
Other Comprehensive Income — detail
+ Other Comprehensive Income1.2-20.8-2.7
+ Items NOT to be Reclassified to P&L0.51.51.7
+ Tax on Items NOT to be Reclassified0.10.40.4
+ Items to be Reclassified to P&L1.0-31.7-7.7
+ Tax on Items to be Reclassified0.2-9.8-3.7
Per Share — as-filed variants
Basic EPS — Continuing Operations8.8316.6317.17
Diluted EPS — Continuing Operations8.6116.4316.93
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1,228.81,621.61,675.7
Gross Margin %72.5173.9674.46
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)227.7474.2491.4
− Exceptional Items (reconciliation)0.0-8.0-8.0
Net Income Adj (tax-effected)170.1354.9367.7
EPS Adj8.8316.9217.45
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.00
Paid Up Equity Capital20.821.221.2
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.